About KRR1 small subunit processome component homolog
KRR1 small subunit processome component homolog (KRR1) is a protein
from Homo sapiens identified by UniProt accession
Q13601, 381 residues long.
MolForge cross-references it against 0 known binders and
20 disease associations.
Target properties
| Protein name | KRR1 small subunit processome component homolog |
| UniProt accession | Q13601 |
| Gene | KRR1 |
| Organism | Homo sapiens |
| Length | 381 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (20)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.49
- polycystic ovary syndrome · score 0.22
- age at menopause · score 0.19
- cup-to-disc ratio measurement · score 0.15
- intrathoracic organ injury · score 0.13
- metabolite measurement · score 0.11
- bone density · score 0.08
- urate measurement · score 0.08
- goiter · score 0.05
- Spontaneous pneumothorax · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q13601-F1 | alphafold | PREDICTED | 81.13 | — |
Amino-acid sequence (381 residues)
MASPSLERPE KGAGKSEFRN QKPKPENQDE SELLTVPDGW KEPAFSKEDN PRGLLEESSF ATLFPKYREA YLKECWPLVQ KALNEHHVNA TLDLIEGSMT VCTTKKTFDP YIIIRARDLI KLLARSVSFE QAVRILQDDV ACDIIKIGSL VRNKERFVKR RQRLIGPKGS TLKALELLTN CYIMVQGNTV SAIGPFSGLK EVRKVVLDTM KNIHPIYNIK SLMIKRELAK DSELRSQSWE RFLPQFKHKN VNKRKEPKKK TVKKEYTPFP PPQPESQIDK ELASGEYFLK ANQKKRQKME AIKAKQAEAI SKRQEERNKA FIPPKEKPIV KPKEASTETK IDVASIKEKV KKAKNKKLGA LTAEEIALKM EADEKKKKKK K
Explore KRR1 small subunit processome component homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets